Screener
BioCryst Pharmaceuticals BCRX Gain (loss) on extinguishment of debt
Gain (loss) on extinguishment of debt at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnExtinguishmentOfDebt.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income | 2,434 | 2,516 | 4,690 | 5,540 |
| Interest expense | (21,712) | (21,582) | (41,491) | (45,076) |
| Foreign currency gains (losses), net | 27 | (63) | (198) | (62) |
| Loss on extinguishment of debt | — | (4,171) | — | (4,171) |
| Other income (expense), net | 260 | — | (1,202) | — |
| Total other expense, net | (18,991) | (23,300) | (38,201) | (43,769) |
| Income (loss) before income taxes | 79,474 | 6,486 | (641,334) | 7,244 |
| Income tax expense | 1,079 | 1,401 | 2,083 | 2,127 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's gain (loss) on extinguishment of debt?
- BioCryst Pharmaceuticals (BCRX) reported gain (loss) on extinguishment of debt of $0 in Q2 2026.
- How has BioCryst Pharmaceuticals's gain (loss) on extinguishment of debt changed year-over-year?
- BioCryst Pharmaceuticals's gain (loss) on extinguishment of debt increased by 100.0% year-over-year, from -$4.17M to $0.
- What is the long-term trend for BioCryst Pharmaceuticals's gain (loss) on extinguishment of debt?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's gain (loss) on extinguishment of debt has grown at a -32.3% compound annual growth rate (CAGR), from $55.84M to -$17.33M.
- What does gain (loss) on extinguishment of debt mean?
- Gains or losses from retiring debt before maturity — gains when debt is repurchased below par, losses when premiums are paid for early redemption.
Ask your AI about BioCryst Pharmaceuticals's gain (loss) on extinguishment of debt.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude